Plus Therapeutics Inc (PSTV) Harga & Berita Saham

(USD)	Sep 2025	Perubahan Y/Y
Pendapatan	1,40 jt	-4,05%
Biaya operasional	3,44 jt	43,64%
Penghasilan bersih	-4,42 jt	-53,90%
Margin laba bersih	-316,61	-60,40%
Penghasilan per saham	-0,04	89,19%
EBITDA	-4,40 jt	-22,36%
Tarif pajak efektif	—	—

Neraca

Total aset

Total liabilitas

(USD)	Sep 2025	Perubahan Y/Y
Investasi tunai jangka pdk	16,60 jt	246,72%
Total aset	18,67 jt	167,56%
Total liabilitas	13,62 jt	12,05%
Total ekuitas	5,05 jt	—
Saham yang beredar	137,43 jt	—
Harga terhadap nilai buku	14,57	—
Tingkat pengembalian aset	-77,22%	—
Tingkat pengembalian modal	-154,14%	—

Arus Kas

Perubahan kas bersih

(USD)	Sep 2025	Perubahan Y/Y
Penghasilan bersih	-4,42 jt	-53,90%
Kas dari operasi	-2,55 jt	30,76%
Kas dari investasi	1,30 jt	14.511,11%
Kas dari pembiayaan	12,31 jt	—
Perubahan kas bersih	11,06 jt	399,70%
Arus kas bebas	-972,25 rb	88,40%

Tentang

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company headquartered in Houston, Texas, that develops targeted radiotherapeutics and diagnostic services for brain and central nervous system cancers. The company’s lead therapeutic candidate, marketed as REYOBIQ™, is an investigational liposomal radiopharmaceutical under clinical evaluation for recurrent glioblastoma, leptomeningeal metastases, and certain pediatric brain cancers. Plus Therapeutics also commercialized a molecular diagnostic service, CNSide®. Wikipedia

Didirikan

1996

Kantor pusat

Austin, Texas
Amerika Serikat

Situs

plustherapeutics.com

Karyawan